These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28383390)

  • 41. Early intensification with abacavir in subjects at high risk for incomplete viral suppression.
    Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K;
    Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706
    [No Abstract]   [Full Text] [Related]  

  • 42. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection].
    Gaba S; Mortier E; Branger C; Vinceneux P
    Presse Med; 2005 Jun; 34(10 Suppl):1S14-5. PubMed ID: 16025662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of HIV-1 drug resistant mutations and virologic failure.
    Makwaga O; Mulama DH; Muoma J; Mwau M
    Pan Afr Med J; 2021; 39():180. PubMed ID: 34584606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.
    Heredia A; Margolis D; Oldach D; Hazen R; Le N; Redfield R
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):406-7. PubMed ID: 10634204
    [No Abstract]   [Full Text] [Related]  

  • 51. Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.
    Katusiime C; Ocama P; Kambugu A
    Afr Health Sci; 2014 Sep; 14(3):679-81. PubMed ID: 25352888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update of the drug resistance mutations in HIV-1: Spring 2008.
    Johnson VA; Brun-Vezinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2008; 16(1):62-8. PubMed ID: 18441382
    [No Abstract]   [Full Text] [Related]  

  • 53. Abacavir-based Regimen for HIV-infected Children and Adolescents.
    Pareek P; Singh DK; Rai R; Srivastava A; Maurya M
    Indian Pediatr; 2019 Aug; 56(8):685-686. PubMed ID: 31477651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients.
    Gallego O; de Mendoza C; Corral A; Soriano V
    AIDS; 2003 Apr; 17(6):919-21. PubMed ID: 12660542
    [No Abstract]   [Full Text] [Related]  

  • 55. The pharmacology of HIV drug resistance.
    Zdanowicz MM
    Am J Pharm Educ; 2006 Oct; 70(5):100. PubMed ID: 17149429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Possibility of HIV-1 resistance mutations in cerebrospinal fluid from persons receiving suppressive therapy.
    Seligman SJ
    J Infect Dis; 2011 Jul; 204(1):174; author reply 174-5. PubMed ID: 21628673
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV Drug Resistance in Kenyan Infants Diagnosed With HIV and Their Mothers.
    Khamadi S; Lwembe R; Maosa N; Maloba M; Wexler C; Sandbulte M; Goggin K; Babu S; Finocchario-Kessler S
    Pediatr Infect Dis J; 2022 Apr; 41(4):312-314. PubMed ID: 34955520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prevalence of antiretroviral resistance in Uruguayan children and adolescents infected with the human immunodeficiency virus in the Reference Center HIV-AIDS. Centro Hospitalario Pereira Rossell, Montevideo, Uruguay].
    González V; Gutiérrez S
    Rev Chilena Infectol; 2018; 35(5):509-517. PubMed ID: 30724998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The challenge of antiretroviral drug resistance in HIV-1-infected children.
    Shafer RW
    J Pediatr (Rio J); 2009; 85(2):91-4. PubMed ID: 19319452
    [No Abstract]   [Full Text] [Related]  

  • 60. Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1.
    Geretti AM; Smith M; Watson C; Mullen J; Osner N; O'Shea S; Chrystie I; Zuckerman M; Easterbrook P
    AIDS; 2002 Nov; 16(17):2358-60. PubMed ID: 12441818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.